Silvia Franceschi

Silvia Franceschi

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Silvia Franceschi

Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Aviano Italy

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CMCatherine de Martel
Catherine de Martel
MPMartyn Plummer
Martyn Plummer
JVJerome Vignat
Jerome Vignat
SFSilvia Franceschi
Silvia Franceschi
HPV is the cause of almost all cervical cancer and is responsible for a substantial fraction of other anogenital cancers and oropharyngeal cancers. Understanding the HPV‐attributable cancer burden can boost programs of HPV vaccination and HPV‐based cervical screening. Attributable fractions (AFs) and the relative contributions of different HPV types were derived from published studies reporting on the prevalence of transforming HPV infection in cancer tissue. Maps of age‐standardized incidence rates of HPV‐attributable cancers by country from GLOBOCAN 2012 data are shown separately for the cervix, other anogenital tract and head and neck cancers. The relative contribution of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 was also estimated. 4.5% of all cancers worldwide (630,000 new cancer cases per year) are attributable to HPV: 8.6% in women and 0.8% in men. AF in women ranges from 20% in India and sub‐Saharan Africa. Cervix accounts for 83% of HPV‐attributable cancer, two‐thirds of which occur in less developed countries. Other HPV‐attributable anogenital cancer includes 8,500 vulva; 12,000 vagina; 35,000 anus (half occurring in men) and 13,000 penis. In the head and neck, HPV‐attributable cancers represent 38,000 cases of which 21,000 are oropharyngeal cancers occurring in more developed countries. The relative contributions of HPV16/18 and HPV6/11/16/18/31/33/45/52/58 are 73% and 90%, respectively. Universal access to vaccination is the key to avoiding most cases of HPV‐attributable cancer. The preponderant burden of HPV16/18 and the possibility of cross‐protection emphasize the importance of the introduction of more affordable vaccines in less developed countries.

1 June 2012 in The Lancet Oncology
Verified
Journal Article
Closed access
CMCatherine de Martel
Catherine de Martel
JFJacques Ferlay
Jacques Ferlay
SFSilvia Franceschi
Silvia Franceschi
JVJérôme Vignat
Jérôme Vignat
FBFreddie Bray
Freddie Bray
MPMartyn Plummer
Martyn Plummer

1 February 2005 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
AKAimee R. Kreimer
Aimee R. Kreimer
GCGary M. Clifford
Gary M. Clifford
PBPeter Boyle
Peter Boyle
SFSilvia Franceschi
Silvia Franceschi
Mucosal human papillomaviruses (HPV) are the cause of cervical cancer and likely a subset of head and neck squamous cell carcinomas (HNSCC), yet the global prevalence and type distribution of HPV in HNSCC remains unclear. We systematically reviewed published studies of HNSCC biopsies that employed PCR-based methods to detect and genotype HPV to describe the prevalence and type distribution of HPV by anatomic cancer site. Geographic location and study size were investigated as possible sources of variability. In the 5,046 HNSCC cancer specimens from 60 studies, the overall HPV prevalence was 25.9% [95% confidence interval (95% CI), 24.7-27.2]. HPV prevalence was significantly higher in oropharyngeal SCCs (35.6% of 969; 95% CI, 32.6-38.7) than oral SCCs (23.5% of 2,642; 95% CI, 21.9-25.1) or laryngeal SCCs (24.0% of 1,435; 95% CI, 21.8-26.3). HPV16 accounted for a larger majority of HPV-positive oropharyngeal SCCs (86.7%; 95% CI, 82.6-90.1) compared with HPV-positive oral SCCs (68.2%; 95% CI, 64.4-71.9) and laryngeal SCCs (69.2%; 95% CI, 64.0-74.0). Conversely, HPV18 was rare in HPV-positive oropharyngeal SCCs (2.8%; 95% CI, 1.3-5.3) compared with other head and neck sites [34.1% (95% CI, 30.4-38.0) of oral SCCs and 17.0% (95% CI, 13.0-21.6) of laryngeal SCCs]. Aside from HPV16 and HPV18, other oncogenic HPVs were rarely detected in HNSCC. Tumor site–specific HPV prevalence was higher among studies from North America compared with Europe and Asia. The high HPV16 prevalence and the lack of HPV18 in oropharyngeal compared with other HNSCCs may point to specific virus-tissue interactions. Small sample size and publication bias complicate the assessment of the prevalence of HPV in head and neck sites beyond the oropharynx.

1 November 2012 in Vaccine
Verified
Journal Article
Closed access
DFDavid Forman
David Forman
CMCatherine de Martel
Catherine de Martel
CLCharles J. Lacey
Charles J. Lacey
ISIsabelle Soerjomataram
Isabelle Soerjomataram
JLJoannie Lortet-Tieulent
Joannie Lortet-Tieulent
SFSilvia Franceschi
Silvia Franceschi

1 September 2016 in The Lancet Global Health
Verified
Journal Article
Open access
MPMartyn Plummer
Martyn Plummer
CMCatherine de Martel
Catherine de Martel
JVJerome Vignat
Jerome Vignat
JFJacques Ferlay
Jacques Ferlay
FBFreddie Bray
Freddie Bray
SFSilvia Franceschi
Silvia Franceschi
Infections with certain viruses, bacteria, and parasites are strong risk factors for specific cancers. As new cancer statistics and epidemiological findings have accumulated in the past 5 years, we aimed to assess the causal involvement of the main carcinogenic agents in different cancer types for the year 2012. We considered ten infectious agents classified as carcinogenic to human beings by the International Agency for Research on Cancer. We calculated the number of new cancer cases in 2012 attributable to infections by country, by combining cancer incidence estimates (from GLOBOCAN 2012) with estimates of attributable fraction (AF) for the infectious agents. AF estimates were calculated from the prevalence of infection in cancer cases and the relative risk for the infection (for some sites). Estimates of infection prevalence, relative risk, and corresponding 95% CIs for AF were obtained from systematic reviews and pooled analyses. Of 14 million new cancer cases in 2012, 2·2 million (15·4%) were attributable to carcinogenic infections. The most important infectious agents worldwide were Helicobacter pylori (770 000 cases), human papillomavirus (640 000), hepatitis B virus (420 000), hepatitis C virus (170 000), and Epstein-Barr virus (120 000). Kaposi's sarcoma was the second largest contributor to the cancer burden in sub-Saharan Africa. The AFs for infection varied by country and development status-from less than 5% in the USA, Canada, Australia, New Zealand, and some countries in western and northern Europe to more than 50% in some countries in sub-Saharan Africa. A large potential exists for reducing the burden of cancer caused by infections. Socioeconomic development is associated with a decrease in infection-associated cancers; however, to reduce the incidence of these cancers without delay, population-based vaccination and screen-and-treat programmes should be made accessible and available. Fondation de France.

25 May 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JSJennifer S. Smith
Jennifer S. Smith
LLLisa Lindsay
Lisa Lindsay
BHBrooke Hoots
Brooke Hoots
JKJessica Keys
Jessica Keys
SFSilvia Franceschi
Silvia Franceschi
GCGary M. Clifford
Gary M. Clifford
Data on human papillomavirus (HPV) type distribution in invasive and pre‐invasive cervical cancer is essential to predict the future impact of HPV16/18 vaccines and HPV‐based screening tests. A meta‐analyses of HPV type distribution in invasive cervical cancer (ICC) and high‐grade squamous intraepithelial lesions (HSIL) identified a total of 14,595 and 7,094 cases, respectively. In ICC, HPV16 was the most common, and HPV18 the second most common, type in all continents. Combined HPV16/18 prevalence among ICC cases was slightly higher in Europe, North America and Australia (74–77%) than in Africa, Asia and South/Central America (65–70%). The next most common HPV types were the same in each continent, namely HPV31, 33, 35, 45, 52 and 58, although their relative importance differed somewhat by region. HPV18 was significantly more prevalent in adeno/adenosquamous carcinoma than in squamous cell carcinoma, with the reverse being true for HPV16, 31, 33, 52 and 58. Among HSIL cases, HPV16/18 prevalence was 52%. However, HPV 16, 18 and 45 were significantly under‐represented, and other high‐risk HPV types significantly over‐represented in HSIL compared to ICC, suggesting differences in type‐specific risks for progression. Data on HPV‐typed ICC and HSIL cases were particularly scarce from large regions of Africa and Central Asia.